Study of claudin-4 in the diagnosis and treatment of endometrial carcinoma

• Published in: Chung-hua fu chʿan kʿo tsa chih Vol. 48; no. 10; p. 768
• Main Authors: Pan, Xiao-yu, Li, Xue, Che, Yan-ci, Li, Xin, Zhang, Yun
• Format: Journal Article
• Language: Chinese
• Published: China 01.10.2013
• Subjects: Animals; Cell Line, Tumor; Cisplatin - administration & dosage; Cisplatin - pharmacology; Claudin-4 - genetics; Claudin-4 - metabolism; Disease Models, Animal; Endometrial Hyperplasia - metabolism; Endometrial Hyperplasia - pathology; Endometrial Neoplasms - metabolism; Endometrial Neoplasms - pathology; Female; Gene Expression Regulation, Neoplastic - drug effects; Humans; Immunohistochemistry; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Paclitaxel - administration & dosage; Paclitaxel - pharmacology; Real-Time Polymerase Chain Reaction; RNA, Messenger - genetics; RNA, Messenger - metabolism; Transplantation, Heterologous
• ISSN: 0529-567X

To clarify the role of claudin-4 in endometrial tumorigenesis and explore claudin-4 be as potentially useful agent in the treatment of endometrial carcinoma. The expression of claudin-4 in 62 endometrioid endometrial carcinoma (EEC), 30 atypical hyperplasia endometrial tissue and 60 human normal endometrium was determined using immunohistochemistry and real-time PCR. Ninety female BALB/c mice were transplanted with Ishikawa endometrial cancer cells, which were divided into three groups with different intraperitoneal treatments with cisplatin, paclitaxel and saline solution. After the observation period, the tumors were extracted and stained with monoclonal antibody against claudin-4. The messenger RNA expression of claudin-4 was also detected using real-time PCR. Among the EEC samples, 34% (21/62) showed medium staining for claudin-4 and 66% (41/62) showed intense staining. In atypical hyperplasia group, 27% (8/30) showed weak staining, 53% (16/30) showed medium staining and 20% (6/30) showed intense staining